HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12.

Abstract
A novel anti-tumor platinum(IV) complex, coded as LA-12, with a bulky adamantylamine ligand displaying oral activity was prepared and its oral activity was evaluated. The murine ADJ/PC6 plasmacytoma and human A2780 ovarian carcinoma tumor model were used to evaluate the in vivo anti-tumor activity of a single dose and also of repeated doses with comparison to the activity of cisplatin and of the platinum(IV) complex satraplatin. The acute toxicity of LA-12 in mice is relatively low (maximum tolerated dose 1000 mg/kg), and the effective dose is comparable to that of cisplatin and higher than that of satraplatin. The therapeutic index derived from this is very high (250). In the human tumor model, two repeated dose schedule regimens were evaluated. LA-12 exerted a significantly higher anti-tumor activity than other substances, i.e. cisplatin and satraplatin, in repeated doses on the murine ADJ/PC6 plasmacytoma tumor model. The dailyx5 repeated dose regimen was selected for further evaluation.
AuthorsPetr Sova, Adolf Mistr, Ales Kroutil, Frantisek Zak, Pavla Pouckova, Marie Zadinova
JournalAnti-cancer drugs (Anticancer Drugs) Vol. 16 Issue 6 Pg. 653-7 (Jul 2005) ISSN: 0959-4973 [Print] England
PMID15930894 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Organoplatinum Compounds
  • bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV)
  • satraplatin
  • Amantadine
Topics
  • Adenocarcinoma (drug therapy)
  • Administration, Oral
  • Amantadine (administration & dosage, analogs & derivatives)
  • Animals
  • Antineoplastic Agents (administration & dosage)
  • Disease Models, Animal
  • Drug Screening Assays, Antitumor (methods)
  • Female
  • Humans
  • Maximum Tolerated Dose
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred Strains
  • Organoplatinum Compounds (administration & dosage)
  • Ovarian Neoplasms (drug therapy)
  • Plasmacytoma (drug therapy)
  • Tumor Cells, Cultured
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: